{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "CJC-1295 and ipamorelin can stimulate GH, but the marketed combination has no verified human physical-recovery benefit in this bounded review.",
  "implications": "The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.",
  "limitations": "56 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}